High-dose flu vaccine beneficial for older people with lung disease
· Medical Xpressby European Respiratory Society
edited by Swati Mestri, reviewed by Robert Egan
Swati Mestri
Scientific Editor
Meet our editorial team
Behind our editorial process
Robert Egan
Senior Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
trusted source
proofread
The GIST Add as preferred source
The risk of being hospitalized for flu or pneumonia can be reduced with a high-dose flu vaccine for older people with chronic lung disease, according to the combined results of two large clinical trials presented at the European Respiratory Society (ERS) Congress in Barcelona, Spain.
The research was presented by Dr. Lisa Steen Duus from Gentofte Hospital, Copenhagen, Denmark. She said, "Flu can be particularly serious for older people with chronic lung disease, such as asthma and COPD. They are more likely to develop complications, including pneumonia, worsening of their existing lung disease and hospitalization.
"Although high-dose flu vaccines are designed to produce a stronger immune response in older adults, there has been limited randomized evidence specifically showing whether they provide better protection against serious illness in people with chronic lung disease. We therefore wanted to investigate whether a high-dose vaccine could reduce hospitalizations in this particularly vulnerable group."
The new research combines the results of two gold-standard randomized controlled trials comparing a high-dose flu vaccine with a standard-dose vaccine in people 65 and older. One trial ran in Denmark over three flu seasons (2022–23, 2023–24 and 2024–25), and one ran in Galicia, Spain, over two flu seasons (2023–24 and 2024–25). Analysis of these trials has already shown that the high-dose vaccine is beneficial in older people overall.
In the new study, researchers looked specifically at trial participants who had a chronic lung disease, including asthma, bronchiectasis, bronchitis, chronic obstructive pulmonary disease (COPD), cystic fibrosis, emphysema, interstitial pulmonary disease, lung transplantation, respiratory tuberculosis and sarcoidosis. Between the two studies, this was 31,976 people, just under 7% of the total 466,320 trial participants.
Around half of the participants were randomly allocated to receive a standard dose of flu vaccine. The other half received a flu vaccine containing four times as much active ingredient that stimulates the immune response.
Researchers monitored the participants and recorded those who were hospitalized from 14 days after their vaccination until the following May, when the flu season is largely over in Europe.
The high-dose flu vaccine reduced hospital admissions for flu or pneumonia by 8.8% compared with the standard-dose vaccine. The high-dose vaccine also reduced hospitalizations for several other conditions, including cardiorespiratory disease, and hospitalizations from any cause, compared with the standard-dose vaccine.
Duus said, "For older people with chronic lung disease and their families, these findings provide reassurance that high-dose flu vaccination can offer better protection against serious illness requiring hospital treatment than a standard-dose vaccine.
"Being hospitalized creates a considerable burden on patients, families and health care systems, so even a modest reduction could have meaningful public health benefits. For that reason, these results support considering high-dose flu vaccines for older adults, including those with chronic lung disease, when developing vaccination recommendations."
Professor Thomas Wilkinson, chair of the European Respiratory Society's Group on Respiratory Infections and Immunology and based at the University of Southampton in the United Kingdom, who was not involved in the research, said, "A flu infection is unpleasant for anyone, but for some people it can be a serious health risk.
"Older people with lung disease have a greater risk of severe illness, hospitalization and death from flu, which is why the European Respiratory Society recommends annual flu vaccination for this group.
"This research combines the results of two large and well-run studies comparing the standard-dose flu vaccine with a high-dose flu vaccine in people 65 and older. Researchers have looked specifically at people in the trials who had also been diagnosed with a lung disease, such as COPD or asthma. Their analysis shows that a high-dose flu vaccine could be even more beneficial in this group."
Key medical concepts
Clinical categories
Pulmonary medicineCommon illnesses & PreventionPreventive medicineHealthy aging Provided by European Respiratory Society Who's behind this story?
Swati Mestri
Swati Mestri holds a bachelor's degree in Electronics Engineering and has worked as a content editor since 2019. She has experience editing research documents across technology, health care, and materials science, and has a particular interest in technology and space. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: High-dose flu vaccine beneficial for older people with lung disease (2026, September 8) retrieved 9 September 2026 from https://medicalxpress.com/news/2026-09-high-dose-flu-vaccine-beneficial.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.